Sionna Therapeutics, Inc.

SION Healthcare Biotechnology

In the quarter to June 2026, EPS fell 61.0% and free cash flow fell 22.4%, each against the same quarter a year earlier.

3.89 0.19 −4.66%
Market cap
$184.5M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+7 more TTM periods

(68.36%) (105.18%) (26.74%) (32.34%)
ROA
(36.13%) (29.42%) (25.36%) (30.66%)
ROIC
(71.16%) (78.38%) (85.80%) (125.00%)
Return on Tangible Assets
(28.89%) (32.45%) (40.12%) (46.99%)
Free Cash Flow per Share
(1.39) (1.67) (1.60) (1.68)
Free Cash Flow
(61.65) (66.67) (71.85) (75.92)
Other line items

Show all line items

Columns are period end dates